Background

EMA announced that the European Parliament and the EU Council have reached a provisional agreement on the Essential Medicines Act. As global supply chain disruptions become more frequent, ensuring a stable supply of essential medicines has emerged as a critical priority.

Key Provisions

The legislation clarifies the definition of essential medicines and strengthens transparency in the manufacturing and distribution stages. It introduces a supply‑chain resilience concept, requiring early identification of risk factors and the development of response strategies. This imposes new regulatory requirements on pharmaceutical manufacturers.

Impact on the Industry

Manufacturers are likely to need increased investment in production facilities and inventory management. At the same time, diversifying supply chains and establishing emergency response plans can enhance long‑term competitiveness. For patients, the risk of drug shortages is expected to decline, ensuring continuity of therapy.

Market Outlook and Challenges

Drug shortage incidents are rising across the EU, and implementation of the law could raise market entry barriers. However, higher compliance costs may burden small and medium‑sized enterprises. Investors should closely monitor these regulatory shifts and consider portfolio adjustments.